(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China...
Stats | |
---|---|
Dagens volum | 10.09M |
Gjennomsnittsvolum | 17.65M |
Markedsverdi | 14.58B |
EPS | HKD0 ( 2024-03-20 ) |
Neste inntjeningsdato | ( HKD0 ) 2024-06-19 |
Last Dividend | HKD0.100 ( 2023-06-27 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 9.07 |
ATR14 | HKD0.0120 (0.20%) |
Volum Korrelasjon
3SBio Inc Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
3SBio Inc Korrelasjon - Valuta/Råvare
3SBio Inc Økonomi
Annual | 2023 |
Omsetning: | HKD7.82B |
Bruttogevinst: | HKD6.64B (84.98 %) |
EPS: | HKD0.620 |
FY | 2023 |
Omsetning: | HKD7.82B |
Bruttogevinst: | HKD6.64B (84.98 %) |
EPS: | HKD0.620 |
FY | 2022 |
Omsetning: | HKD6.86B |
Bruttogevinst: | HKD5.67B (82.69 %) |
EPS: | HKD0.780 |
FY | 2021 |
Omsetning: | HKD6.38B |
Bruttogevinst: | HKD5.28B (82.67 %) |
EPS: | HKD0.650 |
Financial Reports:
No articles found.
3SBio Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.100 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0685 | 2018-06-29 |
Last Dividend | HKD0.100 | 2023-06-27 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | HKD0.369 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.64 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.29 | |
Div. Directional Score | 8.05 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9928.HK | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
2180.HK | Ex Dividend Knight | 2023-07-03 | Annually | 0 | 0.00% | |
1181.HK | Ex Dividend Knight | 2023-09-13 | Annually | 0 | 0.00% | |
0257.HK | Ex Dividend Junior | 2023-09-25 | Semi-Annually | 0 | 0.00% | |
3888.HK | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
1755.HK | Ex Dividend Knight | 2023-07-03 | Annually | 0 | 0.00% | |
0798.HK | Ex Dividend Junior | 2023-06-20 | Annually | 0 | 0.00% | |
2338.HK | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
1313.HK | Ex Dividend Junior | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
0373.HK | Ex Dividend Junior | 2023-05-04 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.198 | 1.500 | 6.04 | 9.05 | [0 - 0.5] |
returnOnAssetsTTM | 0.0656 | 1.200 | 7.81 | 9.38 | [0 - 0.3] |
returnOnEquityTTM | 0.112 | 1.500 | 9.86 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.47 | 0.800 | 2.67 | 2.14 | [1 - 3] |
quickRatioTTM | 1.901 | 0.800 | 3.52 | 2.82 | [0.8 - 2.5] |
cashRatioTTM | 0.722 | 1.500 | 7.10 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.204 | -1.500 | 6.59 | -9.89 | [0 - 0.6] |
interestCoverageTTM | 23.36 | 1.000 | 2.46 | 2.46 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.485 | 2.00 | 9.84 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.353 | 2.00 | 9.82 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.344 | -1.500 | 8.62 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.850 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.300 | 1.000 | 5.99 | 5.99 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.245 | 1.000 | 9.75 | 9.75 | [0.2 - 2] |
assetTurnoverTTM | 0.331 | 0.800 | -1.128 | -0.902 | [0.5 - 2] |
Total Score | 10.81 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.87 | 1.000 | 9.21 | 0 | [1 - 100] |
returnOnEquityTTM | 0.112 | 2.50 | 9.91 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.353 | 2.00 | 9.88 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.778 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.485 | 2.00 | 9.84 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.152 | 1.000 | 8.71 | 0 | [0.1 - 0.5] |
Total Score | 5.29 |
3SBio Inc
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and DanaFarber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.